Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study-Reference-Cited by-同舟云学术

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

Published:2013-07 Issue:7 Volume:24 Page:1813-1821
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Slovin S.F.,Higano C.S.,Hamid O.,Tejwani S.,Harzstark A.,Alumkal J.J.,Scher H.I.,Chin K.,Gagnier P.,McHenry M.B.,Beer T.M.

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/7/1813/468727/mdt107.pdf

Reference48 articles.

1. Emerging role of immunotherapy in the management of prostate cancer;Slovin;Oncology (Williston Park),2007

2. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

5. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

Cited by 474 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of immunotherapy in urological cancers;Archivio Italiano di Urologia e Andrologia;2024-05-30

2. Immunogenicity of radiotherapy on bone metastases from prostate adenocarcinoma: What is the future for the combination with radiotherapy/immunotherapy?;Tumori Journal;2024-05-15

3. Combination low-dose cyclophosphamide with check-point blockade and ionizing radiation promote an abscopal effect in mouse models of melanoma;Journal of Cancer Research and Therapeutics;2024-04

4. The abscopal effect: mechanism of occurrence and prospects of using it in therapy of metastatic cancer;Siberian journal of oncology;2024-03-20

5. INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors;Cancer Immunology, Immunotherapy;2024-02-13